Skip Navigation
ChemIDplus Lite•Browse•Advanced

Substance Name: Heparin
RN: 9005-49-6
InChIKey: HTTJABKRGRZYRN-UHFFFAOYSA-N

Note

  • A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.

Molecular Formula

  • Unspecified

Molecular Weight

  • 1134.9248
 

Classification Codes

  • Anticoagulant
  • Anticoagulants
  • Antithrombotic
  • Antiviral (COVID-19)
  • Cardiovascular Agents
  • Drug / Therapeutic Agent
  • Fibrin Modulating Agents
  • Fibrinolytic Agents
  • Hematologic Agents
  • Human Data
  • Mutation Data
  • Natural Product
  • Reproductive Effect

Names and Synonyms

Results Name

  • Heparin

Name of Substance

  • Adomiparin [USAN]
  • Bemiparin
  • Certoparin
  • CY 222
  • Fluxum
  • Heparin
  • Heparin [BAN]
  • Parnaparin
  • Reviparin
  • Sandoparin
  • Semuloparin [USAN:INN]
  • Tinzaparin

MeSH Heading

  • Heparin

Synonyms

  • Adomiparin
  • alpha-Heparin
  • Ardeparin
  • Arteven
  • AVE-5026
  • Bemiparin
  • Certoparin
  • Clexane
  • Clivarin
  • Clivarine
  • CY 216
  • CY 222
  • Dalteparin
  • Depo-Heparin
  • EINECS 232-681-7
  • Eparina
  • Eparina [DCIT]
  • Fluxum
  • FR 860
  • Fragmin A
  • Fragmin B
  • Fraxiparin
  • Hed-heparin
  • Heparin CY 216
  • Heparin sulfate
  • Heparina
  • Heparina [INN-Spanish]
  • Heparinate
  • Heparine
  • Heparine [INN-French]
  • Heparinic acid
  • Heparinum
  • Heparinum [INN-Latin]
  • Hepathrom
  • HSDB 3094
  • KB 101
  • Lipo-hepin
  • Liquaemin
  • Liquemin
  • LMWH
  • M 118
  • M 118REH
  • M118
  • Multiparin
  • Nadroparin
  • Nadroparine
  • Novoheparin
  • Octaparin
  • OP 386
  • OP 622
  • Pabyrin
  • Parnaparin
  • Parvoparin
  • Pularin
  • Reviparin
  • Sandoparin
  • Semuloparin
  • Subeparin
  • Sublingula
  • Thromboliquine
  • Tinzaparin
  • Triofiban
  • UNII-1K5KDI46KZ
  • UNII-4QW4AN84NQ
  • UNII-5R0L1D739E
  • UNII-7UQ7X4Y489
  • UNII-9816XA9004
  • UNII-E47C0NF7LV
  • UNII-M316WT19D8
  • UNII-P776JQ4R2F
  • UNII-S79O08V79F
  • UNII-T2410KM04A
  • UNII-V72OT3K19I
  • UNII-VL0L558GCB
  • Vetren
  • Vitrum AB

Systematic Name

  • Heparin

Registry Numbers

CAS Registry Number

  • 9005-49-6

FDA UNIIs

  • 1K5KDI46KZ
  • 4QW4AN84NQ
  • 5R0L1D739E
  • 7UQ7X4Y489
  • 9816XA9004
  • E47C0NF7LV
  • M316WT19D8
  • P776JQ4R2F
  • S79O08V79F
  • T2410KM04A
  • V72OT3K19I
  • VL0L558GCB

Other Registry Numbers

  • 104521-37-1
  • 11078-24-3
  • 1108625-99-5
  • 1108626-06-7
  • 11129-39-8
  • 37324-73-5
  • 9075-96-1
  • 91449-79-5

System Generated Number

  • 0009005496

Structure Descriptors

InChI

InChI=1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)

InChIKey

HTTJABKRGRZYRN-UHFFFAOYSA-N

Smiles

CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(=O)(=O)O)C(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C(=O)O)C1O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
man TDLo intravenous 3536units/kg/ (3536units/kg)   Southern Medical Journal. Vol. 80, Pg. 1450, 1987.
man TDLo subcutaneous 1857units/kg/ (1857units/kg)   Southern Medical Journal. Vol. 80, Pg. 1450, 1987.
man TDLo subcutaneous 1857units/kg/ (1857units/kg) CARDIAC: OTHER CHANGES Southern Medical Journal. Vol. 80, Pg. 1450, 1987.
mouse LD50 intraperitoneal 1900mg/kg (1900mg/kg) BEHAVIORAL: MUSCLE WEAKNESS

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)		 Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 60, Pg. 507, 1964.
mouse LD50 intravenous 500mg/kg (500mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Arzneimittel-Forschung. Drug Research. Vol. 36, Pg. 1366, 1986.
mouse LD50 subcutaneous 500mg/kg (500mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: MUSCLE WEAKNESS		 Arzneimittel-Forschung. Drug Research. Vol. 36, Pg. 1366, 1986.
rat LD50 oral 1950mg/kg (1950mg/kg)   German Offenlegungsschrift Patent Document. Vol. #2636091,
rat LDLo intraperitoneal 420mg/kg (420mg/kg)   Toxicology and Applied Pharmacology. Vol. 1, Pg. 156, 1959.
women TDLo subcutaneous 30uL/kg/5D-I (0.03mL/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" British Journal of Haematology. Vol. 82, Pg. 620, 1992.
women TDLo subcutaneous 48mg/kg/20D-I (48mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"

BLOOD: HEMORRHAGE		 Australian and New Zealand Journal of Medicine. Vol. 28, Pg. 59, 1998.
women TDLo subcutaneous 1000units/kg/ (1000units/kg)   Southern Medical Journal. Vol. 80, Pg. 1450, 1987.